Influence of electrostatics on the complement regulatory functions of Kaposica, the complement inhibitor of Kaposi's sarcoma-associated herpesvirus

Journal of Immunology

Volumn 184, Issue 4, 2010, Pages 1956-1967

  Pyaram, Kalyani ^a   Kieslich, Chris A ^b   Yadav, Viveka Nand ^a   Morikis, Dimitrios ^b   Sahu, Arvind ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b University of California Riverside   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT INHIBITOR; GLUTAMIC ACID; GLYCINE; KAPOSICA; LYSINE; UNCLASSIFIED DRUG; VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN; KSHV COMPLEMENT CONTROL PROTEIN, HERPESVIRUS 8; VIRUS PROTEIN;

ARTICLE; KAPOSI SARCOMA; NONHUMAN; PRIORITY JOURNAL; STATIC ELECTRICITY; WART VIRUS; COMPLEMENT ALTERNATIVE PATHWAY; GENETICS; HUMAN; HUMAN HERPESVIRUS 8; IMMUNOLOGY; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS;

COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT PATHWAY, ALTERNATIVE; HERPESVIRUS 8, HUMAN; HUMANS; MUTAGENESIS, SITE-DIRECTED; STATIC ELECTRICITY; VIRAL PROTEINS;

EID: 77949905425     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903261     Document Type: Article

References (63)

1. Lachmann, P. J. 2002. Microbial subversion of the immune response. Proc. Natl. Acad. Sci. USA 99: 8461-8462.
2. Sahu, A., and J. D. Lambris. 2001. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol. Rev. 180: 35-48.
3. Cooper, N. R. 1998. Complement and viruses. In The Human Complement System in Health and Disease. J. E. Volanakis, and M. M. Frank, eds. Marcel Dekker, New York, pp. 393-407.
4. Bernet, J., J. Mullick, A. K. Singh, and A. Sahu. 2003. Viral mimicry of the complement system. J. Biosci. 28: 249-264.
5. Carroll, M. C. 2004. The complement system in regulation of adaptive immunity. Nat. Immunol. 5: 981-986.
6. Köhl, J. 2006. The role of complement in danger sensing and transmission. Immunol. Res. 34: 157-176.
7. Mullick, J., A. Kadam, and A. Sahu. 2003. Herpes and pox viral complement control proteins: "the mask of self." Trends Immunol. 24: 500-507.
8. Lambris, J. D., D. Ricklin, and B. V. Geisbrecht. 2008. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6: 132-142.
9. Finlay, B. B., and G. McFadden. 2006. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124: 767-782.
10. Judson, K. A., J.M. Lubinski, M. Jiang,Y. Chang, R. J. Eisenberg,G.H.Cohen, and H. M. Friedman. 2003. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection. J. Virol. 77: 12639-12645.
11. Means, R. E., J. K. Choi, H. Nakamura, Y. H. Chung, S. Ishido, and J. U. Jung. 2002. Immune evasion strategies of Kaposi's sarcoma-associated herpesvirus. Curr. Top. Microbiol. Immunol. 269: 187-201.
12. Kotwal, G. J., S. N. Isaacs, R. McKenzie, M. M. Frank, and B. Moss. 1990. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250: 827-830.
13. Liszewski, M. K., M. K. Leung, R. Hauhart, R. M. Buller, P. Bertram, X. Wang, A. M. Rosengard, G. J. Kotwal, and J. P. Atkinson. 2006. Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J. Immunol. 176: 3725-3734.
14. Rosengard, A. M., Y. Liu, Z. Nie, and R. Jimenez. 2002. Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc. Natl. Acad. Sci. USA 99: 8808-8813.
15. Johnson, J. B., K. Grant, and G. D. Parks. 2009. The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization. J. Virol. 83: 7602-7611.
16. Vanderplasschen, A., E. Mathew, M. Hollinshead, R. B. Sim, and G. L. Smith. 1998. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl. Acad. Sci. USA 95: 7544-7549.
17. Stoiber, H., M. Pruenster, C. G. Ammann, and M. P. Dierich. 2005. Complement-opsonized HIV: the free rider on its way to infection. Mol. Immunol. 42: 153-160.
18. Russo, J. J., R. A. Bohenzky, M. C. Chien, J. Chen, M. Yan, D. Maddalena, J. P. Parry, D. Peruzzi, I. S. Edelman, Y. Chang, and P. S. Moore. 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. USA 93: 14862-14867.
19. Liang, C. Y., J. S. Lee, and J. U. Jung. 2008. Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis. Semin. Cancer Biol. 18: 423-436.
20. Moore, P. S., and Y. Chang. 2003. Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? Annu. Rev. Microbiol. 57: 609-639.
21. Spiller, O. B., M. Robinson, E. O'Donnell, S. Milligan, B. P. Morgan, A. J. Davison, and D. J. Blackbourn. 2003. Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J. Virol. 77: 592-599.
22. Mullick, J., J. Bernet, A. K. Singh, J. D. Lambris, and A. Sahu. 2003. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) open reading frame 4 protein (kaposica) is a functional homolog of complement control proteins. J. Virol. 77: 3878-3881.
23. Spiller, O. B., L. Mark, C. E. Blue, D. G. Proctor, J. A. Aitken, A. M. Blom, and D. J. Blackbourn. 2006. Dissecting the regions of virion-associated Kaposi's sarcoma-associated herpesvirus complement control protein required for complement regulation and cell binding. J. Virol. 80: 4068-4078.
24. Mark, L., W. H. Lee, O. B. Spiller, D. Proctor, D. J. Blackbourn, B. O. Villoutreix, and A. M. Blom. 2004. The Kaposi's sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system. J. Biol. Chem. 279: 45093-45101.
25. Mullick, J., A. K. Singh, Y. Panse, V. Yadav, J. Bernet, and A. Sahu. 2005. Identification of functional domains in kaposica, the complement control protein homolog of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8). J. Virol. 79: 5850-5856.
26. Mullick, J., J. Bernet, A. K. Singh, and A. Sahu. 2004. Kinetic analysis of the interactions of Kaposica, the Kaposi's sarcoma-associated herpesvirus open reading frame 4 protein, with human complement components C3b and C4b. Mol. Immunol. 41: 283.
27. Bernet, J., J. Mullick, Y. Panse, P. B. Parab, and A. Sahu. 2004. Kinetic analysis of the interactions between vaccinia virus complement control protein and human complement proteins C3b and C4b. J. Virol. 78: 9446-9457.
28. Oran, A. E., and D. E. Isenman. 1999. Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35). J. Biol. Chem. 274: 5120-5130. (Pubitemid 129501534)
29. Liszewski, M. K., M. Leung, W. Cui, V. B. Subramanian, J. Parkinson, P. N. Barlow, M. Manchester, and J. P. Atkinson. 2000. Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J. Biol. Chem. 275: 37692-37701.
30. Krych, M., R. Hauhart, and J. P. Atkinson. 1998. Structure-function analysis of the active sites of complement receptor type 1. J. Biol. Chem. 273: 8623-8629.
31. Blom, A. M., J. Webb, B. O. Villoutreix, and B. Dahlbäck. 1999. A cluster of positively charged amino acids in the C4BP a-chain is crucial for C4b binding and factor I cofactor function. J. Biol. Chem. 274: 19237-19245.
32. Sfyroera, G., M. Katragadda, D. Morikis, S. N. Isaacs, and J. D. Lambris. 2005. Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J. Immunol. 174: 2143-2151. (Pubitemid 40223958)
33. Zhang, L., and D. Morikis. 2006. Immunophysical properties and prediction of activities for vaccinia virus complement control protein and smallpox inhibitor of complement enzymes using molecular dynamics and electrostatics. Biophys. J. 90: 3106-3119.
34. Mullick, J., J. Bernet, Y. Panse, S. Hallihosur, A. K. Singh, and A. Sahu. 2005. Identification of complement regulatory domains in vaccinia virus complement control protein. J. Virol. 79: 12382-12393.
35. Singh, A. K., J. Mullick, J. Bernet, and A. Sahu. 2006. Functional characterization of the complement control protein homolog of herpesvirus saimiri: ARG-118 is critical for factor I cofactor activities. J. Biol. Chem. 281: 23119-23128.
36. Pangburn, M. K. 1987. A fluorimetric assay for native C3. The hemolytically active form of the third component of human complement. J. Immunol. Methods 102: 7-14.
37. Sahu, A., S. N. Isaacs, A. M. Soulika, and J. D. Lambris. 1998. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J. Immunol. 160: 5596-5604. (Pubitemid 28267854)
38. Murthy, K. H., S. A. Smith, V. K. Ganesh, K. W. Judge, N. Mullin, P. N. Barlow, C. M. Ogata, and G. J. Kotwal. 2001. Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell 104: 301-311.
39. Larkin, M. A., G. Blackshields, N. P. Brown, R. Chenna, P. A. McGettigan, H. McWilliam, F. Valentin, I. M. Wallace, A. Wilm, R. Lopez, et al. 2007. Clustal W and Clustal X version 2.0. Bioinformatics 23: 2947-2948.
40. Guex, N., and M. C. Peitsch. 1997. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723.
41. Baker, N. A., D. Sept, S. Joseph, M. J. Holst, and J. A. McCammon. 2001. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. USA 98: 10037-10041.
42. Dolinsky, T. J., J. E. Nielsen, J. A. McCammon, and N. A. Baker. 2004. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 32(Web Server issue): W665-W667.
43. Sitkoff, D., K. A. Sharp, and B. Honig. 1994. Accurate calculation of hydration free energies using macroscopic solvent models. J. Phys. Chem. 98: 1978-1988.
44. Humphrey, W., A. Dalke, and K. Schulten. 1996. VMD: visual molecular dynamics. J. Mol. Graph. 14: 33-38, 27-28.
45. Yadav, V. N., K. Pyaram, J. Mullick, and A. Sahu. 2008. Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation. J. Virol. 82: 3283-3294.
46. White, J., P. Lukacik, D. Esser, M. Steward, N. Giddings, J. R. Bright, S. J. Fritchley, B. P. Morgan, S. M. Lea, G. P. Smith, and R. A. Smith. 2004. Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli. Protein Sci. 13: 2406-2415.
47. Pan, Q., R. O. Ebanks, and D. E. Isenman. 2000. Two clusters of acidic amino acids near the NH2 terminus of complement component C4 a9-chain are important for C2 binding. J. Immunol. 165: 2518-2527. (Pubitemid 30660697)
48. Jokiranta, T. S., J. Hellwage, V. Koistinen, P. F. Zipfel, and S. Meri. 2000. Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J. Biol. Chem. 275: 27657-27662.
49. Spiller, O. B., D. J. Blackbourn, L. Mark, D. G. Proctor, and A. M. Blom. 2003. Functional activity of the complement regulator encoded by Kaposi's sarcomaassociated herpesvirus. J. Biol. Chem. 278: 9283-9289.
50. Hourcade, D., M. K. Liszewski, M. Krych-Goldberg, and J. P. Atkinson. 2000. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. Immunopharmacology 49: 103-116.
51. Pangburn, M. K., K. L. Pangburn, V. Koistinen, S. Meri, and A. K. Sharma. 2000. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. J. Immunol. 164: 4742-4751.
52. Soames, C. J., and R. B. Sim. 1997. Interactions between human complement components factor H, factor I and C3b. Biochem. J. 326: 553-561. (Pubitemid 27417236)
53. Lukacik, P., P. Roversi, J. White, D. Esser, G. P. Smith, J. Billington, P. A. Williams, P. M. Rudd, M. R. Wormald, D. J. Harvey, et al. 2004. Complement regulation at the molecular level: the structure of decay-accelerating factor. Proc. Natl. Acad. Sci. USA 101: 1279-1284.
54. Kuttner-Kondo, L. A., M. P. Dybvig, L. M. Mitchell, N. Muqim, J. P. Atkinson, M. E. Medof, and D. E. Hourcade. 2003. A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases. J. Biol. Chem. 278: 52386-52391.
55. Kapadia, S. B., B. Levine, S. H. Speck, and H. W. Virgin, 4th. 2002. Critical role of complement and viral evasion of complement in acute, persistent, and latent γ-herpesvirus infection. Immunity 17: 143-155.
56. Lubinski, J., L. Wang, D. Mastellos, A. Sahu, J. D. Lambris, and H. M. Friedman. 1999. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J. Exp. Med. 190: 1637-1646.
57. Isaacs, S. N., G. J. Kotwal, and B. Moss. 1992. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. USA 89: 628-632.
58. Zhang, L., B. Mallik, and D. Morikis. 2007. Immunophysical exploration of C3d-CR2(CCP1-2) interaction using molecular dynamics and electrostatics. J. Mol. Biol. 369: 567-583.
59. Kuttner-Kondo, L., D. E. Hourcade, V. E. Anderson, N. Muqim, L. Mitchell, D. C. Soares, P. N. Barlow, and M. E. Medof. 2007. Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases. J. Biol. Chem. 282: 18552-18562.
60. Wu, J., and D. Morikis. 2006. Molecular thermodynamics for charged biomacromolecules. Fluid Phase Equilib. 241: 317-333.
61. Wu, J., Y. Q. Wu, D. Ricklin, B. J. Janssen, J. D. Lambris, and P. Gros. 2009. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 10: 728-733.
62. Brodbeck, W. G., D. Liu, J. Sperry, C. Mold, and M. E. Medof. 1996. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. J. Immunol. 156: 2528-2533.
63. Blom, A. M., L. Kask, and B. Dahlbäck. 2001. Structural requirements for the complement regulatory activities of C4BP. J. Biol. Chem. 276: 27136-27144.